2022
Analysis of Severe Illness After Postvaccination COVID-19 Breakthrough Among Adults With and Without HIV in the US
Lang R, Humes E, Coburn SB, Horberg MA, Fathi LF, Watson E, Jefferson CR, Park LS, Gordon KS, Akgün KM, Justice AC, Napravnik S, Edwards JK, Browne LE, Agil DM, Silverberg MJ, Skarbinski J, Leyden WA, Stewart C, Hogan BC, Gebo KA, Marconi VC, Williams CF, Althoff KN. Analysis of Severe Illness After Postvaccination COVID-19 Breakthrough Among Adults With and Without HIV in the US. JAMA Network Open 2022, 5: e2236397. PMID: 36227594, PMCID: PMC9561947, DOI: 10.1001/jamanetworkopen.2022.36397.Peer-Reviewed Original ResearchConceptsBreakthrough COVID-19Breakthrough infectionsHIV statusCohort studySevere illnessMAIN OUTCOMEBreakthrough SARS-CoV-2 infectionCOVID-19 vaccine typesLow CD4 cell countsSARS-CoV-2 infectionCOVID-19Severe immune suppressionCD4 cell countProportion of patientsCells/μLPrevious COVID-19Additional vaccine dosesProportional hazards modelDiscrete-time proportional hazards modelsRisk reduction recommendationsVaccine guidelinesCD4 cellsCumulative incidenceHazard ratioClinical factorsSARS-CoV-2 Testing and Positivity Among Persons With and Without HIV in 6 US Cohorts
Park LS, McGinnis KA, Gordon KS, Justice AC, Leyden W, Silverberg MJ, Skarbinski J, Jefferson C, Horberg M, Certa J, Napravnik S, Edwards JK, Westreich D, Bastarache L, Gangireddy S, Benning L, D'Souza G, Williams C, Althoff KN. SARS-CoV-2 Testing and Positivity Among Persons With and Without HIV in 6 US Cohorts. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2022, 90: 249-255. PMID: 35195574, PMCID: PMC9203911, DOI: 10.1097/qai.0000000000002943.Peer-Reviewed Original ResearchConceptsSARS-CoV-2SARS-CoV-2 testingHIV statusClinical cohortPositive SARS-CoV-2 testSARS-CoV-2 positivitySARS-CoV-2 testCOVID-19-related outcomesProportion of PWHProportion of patientsSARS-CoV-2 variantsCOVID-19 vaccineLatest therapeutic optionsTherapeutic optionsUS cohortPositivity proportionInterval cohortPWHPWOHCohortHealth systemDiverse cohortHIVPositivityTesting proportions
2011
A Comparison of Treatment Eligibility for Hepatitis C Virus in HCV-Monoinfected Versus HCV/HIV-Coinfected Persons in Electronically Retrieved Cohort of HCV-Infected Veterans
Butt AA, McGinnis K, Skanderson M, Justice AC. A Comparison of Treatment Eligibility for Hepatitis C Virus in HCV-Monoinfected Versus HCV/HIV-Coinfected Persons in Electronically Retrieved Cohort of HCV-Infected Veterans. AIDS Research And Human Retroviruses 2011, 27: 973-979. PMID: 21338329, PMCID: PMC3719436, DOI: 10.1089/aid.2011.0004.Peer-Reviewed Original ResearchConceptsChronic obstructive pulmonary diseaseHepatitis C virusDecompensated liver diseaseHCV-HIVTreatment eligibilityC virusCohort of HCVVA National Patient Care DatabaseNational Patient Care DatabasePharmacy Benefits Management databaseHCV treatment eligibilityHCV-HIV coinfectionRecent alcohol abuseHCV/HIVCurrent treatment guidelinesProportion of patientsObstructive pulmonary diseaseCoronary artery diseasePatient Care DatabaseActual clinical settingsCoinfected PersonsAggressive managementCommon contraindicationsPharmacy recordsRenal failureA Budget Impact Analysis of Rapid Human Immunodeficiency Virus Screening in Veterans Administration Emergency Departments
Gidwani R, Goetz MB, Kominski G, Asch S, Mattocks K, Samet JH, Justice A, Gandhi N, Needleman J. A Budget Impact Analysis of Rapid Human Immunodeficiency Virus Screening in Veterans Administration Emergency Departments. Journal Of Emergency Medicine 2011, 42: 719-726. PMID: 21277144, PMCID: PMC3204328, DOI: 10.1016/j.jemermed.2010.11.038.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virus screeningUsual careEmergency departmentVirus screeningVeteran's Administration emergency departmentsRapid testing programmeTreatment-naïve HIVUsual care armProportion of patientsHIV testing programsRapid testingDistribution of CD4Budget impact analysisDisease severity categoriesDecision analysis modelLow disease prevalenceCare armChart reviewPositive patientsRapid HIVHIV prevalenceLate-stage symptomsDiagnostic testing approachPatientsTest acceptance
2005
Estimating the proportion of patients infected with HIV who will die of comorbid diseases
Braithwaite RS, Justice AC, Chang CC, Fusco JS, Raffanti SR, Wong JB, Roberts MS. Estimating the proportion of patients infected with HIV who will die of comorbid diseases. The American Journal Of Medicine 2005, 118: 890-898. PMID: 16084183, DOI: 10.1016/j.amjmed.2004.12.034.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusComorbid diseasesCombination therapyNaïve human immunodeficiency virusNon-HIV mortalityEffective antiretroviral therapyCells/mm3Proportion of patientsSeparate patient cohortsCopies/mLProportion of deathsLikelihood of deathAntiretroviral therapyObservational cohortHIV infectionTreatment failureViral loadImmunodeficiency virusMean agePatient cohortPatientsSubsequent deathPhenotypic resistanceTherapyCohort